Tesamorelin Source

The sources

Tesamorelin References and Citations

The full list of studies behind every quantitative claim on this site — peer-reviewed trials, pooled analyses, an NIH drug-safety monograph, and recent reviews.

Read the researchBack to overview

How to read this list

Every numbered marker on this site resolves to an entry below. The list spans the two pivotal Phase 3 trials of tesamorelin in HIV-associated lipodystrophy, the JAMA hepatic-fat RCT, the healthy-men mechanistic study, the pooled and predictor analyses, an NIH LiverTox monograph, and recent 2026 reviews and a meta-analysis. Where a study is paywalled, the PubMed identifier and DOI are provided so the abstract and citation can be retrieved. These are the references and citations for the tesamorelin record summarized across this site.

  1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. ↗
  2. Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. ↗
  3. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. ↗
  4. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. ↗
  5. National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): NCBI Bookshelf (NIH); 2018. ↗
  6. Jain S, Desai N, Bhangoo A. Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS. Rev Endocr Metab Disord. 2013;14:113-118. ↗
  7. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95:4291-4304. ↗
  8. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-247. ↗
  9. Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011;25(10):1281-1288. ↗
  10. Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dube MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395-1402. ↗
  11. Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. PLoS One. 2015;10(10):e0140358. ↗
  12. Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA. Effect of tesamorelin in people with HIV with and without dorsocervical fat: post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2023;7(1):e40. ↗
  13. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026. ↗
  14. Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026. ↗
  15. Villegas Meza AD, et al. Injectable peptides in sports medicine: a structured narrative review of evidence, safety, and antidoping implications. JBJS Rev. 2026. ↗
  16. Gonzalez-Sales M, et al. Population pharmacokinetic analysis of tesamorelin (apparent plasma clearance ~1,060 L/h; ~13% higher absorbed fraction by day 14). 2015. PMID 25358450. ↗